Suppr超能文献

不同解剖部位的组织可以塑造和改变肿瘤微环境,从而影响对治疗的反应。

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

机构信息

Cancer Immunology Research Program, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

Tumor Angiogenesis Program, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

出版信息

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

Abstract

The tumor microenvironment can promote tumor growth and reduce treatment efficacy. Tumors can occur in many sites in the body, but how surrounding normal tissues at different anatomical sites affect tumor microenvironments and their subsequent response to therapy is not known.We demonstrated that tumors from renal, colon, or prostate cell lines in orthotopic locations responded to immunotherapy consisting of three agonist antibodies, termed Tri-mAb, to a much lesser extent than the same tumor type located subcutaneously. A tissue-specific response to Tri-mAb was confirmed by ex vivo separation of subcutaneous (SC) or orthotopic tumor cells from stromal cells, followed by reinjection of tumor cells into the opposite site. Compared with SC tumors, orthotopic tumors had a microenvironment associated with a type 2 immune response, related to immunosuppression, and an involvement of alternatively activated macrophages in the kidney model. Orthotopic kidney tumors were more highly vascularized than SC tumors. Neutralizing the macrophage- and Th2-associated molecules chemokine (C-C motif) ligand 2 or interleukin-13 led to a significantly improved therapeutic effect. This study highlights the importance of the tissue of implantation in sculpting the tumor microenvironment. These are important fundamental issues in tumor biology and crucial factors to consider in the design of experimental models and treatment strategies.

摘要

肿瘤微环境可促进肿瘤生长并降低治疗效果。肿瘤可发生在体内许多部位,但周围不同解剖部位的正常组织如何影响肿瘤微环境及其随后对治疗的反应尚不清楚。我们证明,来自肾、结肠或前列腺细胞系的原位肿瘤对免疫疗法的反应要小得多,该免疫疗法由三种激动型抗体(称为 Tri-mAb)组成,而皮下(SC)同一肿瘤类型的反应则要小得多。通过将皮下(SC)或原位肿瘤细胞与基质细胞从组织特异性反应中分离出来,然后将肿瘤细胞重新注入相反的部位,证实了 Tri-mAb 的组织特异性反应。与 SC 肿瘤相比,原位肿瘤的微环境与 2 型免疫反应相关,与免疫抑制有关,并且在肾脏模型中涉及到交替激活的巨噬细胞。与 SC 肿瘤相比,原位肾肿瘤的血管化程度更高。中和巨噬细胞和 Th2 相关分子趋化因子(C-C 基序)配体 2 或白细胞介素 13 可显著改善治疗效果。这项研究强调了植入组织在塑造肿瘤微环境中的重要性。这些是肿瘤生物学中的重要基础问题,也是设计实验模型和治疗策略时必须考虑的关键因素。

相似文献

2
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.OX40、4-1BB 和 CD40 作为癌症免疫治疗的靶点。
Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14.

引用本文的文献

5
Leveraging preclinical models of metastatic breast cancer.利用转移性乳腺癌的临床前模型。
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189163. doi: 10.1016/j.bbcan.2024.189163. Epub 2024 Jul 29.
6
Nanotechnology Applications in Breast Cancer Immunotherapy.纳米技术在乳腺癌免疫治疗中的应用。
Small. 2024 Oct;20(41):e2308639. doi: 10.1002/smll.202308639. Epub 2023 Dec 21.

本文引用的文献

7
The metastatic niche and stromal progression.转移灶微环境和基质进展。
Cancer Metastasis Rev. 2012 Dec;31(3-4):429-40. doi: 10.1007/s10555-012-9373-9.
10
Tumor microenvironment: a main actor in the metastasis process.肿瘤微环境:转移过程中的主要参与者。
Clin Exp Metastasis. 2012 Apr;29(4):381-95. doi: 10.1007/s10585-012-9457-5. Epub 2012 Feb 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验